KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

RTTNews | 955日前
KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Monday that it has terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema (HAE).

This decision was based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial. No patients had concomitant elevation of bilirubin levels and all were asymptomatic.

The KOMPLETE trial is a phase 2 clinical trial evaluating KVD824, an investigational oral plasma kallikrein inhibitor designed for the prevention of attacks in adults living with HAE.

Patients in the trial were randomized to one of three treatment groups, each placebo controlled: 300 mg, 600 mg, 900 mg KVD824 (or placebo), all dosed twice daily.

KalVista continues to recruit the phase 3 KONFIDENT trial assessing sebetralstat (formerly KVD900) as a potential oral, on-demand therapy for HAE attacks, with data anticipated in the second half of 2023.

For More Such Health News, visit rttnews.com

read more
KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector.
RTTNews | 248日前
FTSE 100 Advances Again

FTSE 100 Advances Again

U.K. stocks are moving higher on Friday as investors continue to cheer the recent tariff agreement between U.S. and China, and news about a positive progress in talks between the EU bloc and U.S. for lowering the tariffs from earlier proposed levels.
RTTNews | 40分前
CAC 40 Advances On Easing Trade Tensions

CAC 40 Advances On Easing Trade Tensions

French stocks are up in positive territory on Friday, extending gains from the previous session, amid easing fears of a trade war. Following announcements of U.S.-UK pact, and U.S.-China deal, reports about a positive progress in the EU bloc's discussions with the U.S. for considerable tariff reductions have bolstered investor sentiment.
RTTNews | 1時8分前
DAX Up 0.8%, Looks Set To End Week On Strong Note

DAX Up 0.8%, Looks Set To End Week On Strong Note

German stocks are up firmly in positive territory on Friday, amid easing trade tensions following the U.S.-China deal earlier in the week, and recent reports about a positive progress in the EU bloc's discussions with the U.S. for tariff reductions.
RTTNews | 1時27分前
European Shares Edge Higher In Cautious Trade

European Shares Edge Higher In Cautious Trade

European stocks traded higher on Friday as a slew of weak U.S. economic data suggested the Federal Reserve may have more leeway to cut interest rates later this year.
RTTNews | 2時17分前
Yen Rises Amid Risk-off Mood, BoJ Rate Hike Bets

Yen Rises Amid Risk-off Mood, BoJ Rate Hike Bets

The Japanese yen strengthened against other major currencies in the Asian session on Friday amid risk-off mood, as traders digested the latest settlements on the trade tariff front and remained caution as they awaited more clarity on the developments in trade negotiations with other trade partners.
RTTNews | 2時42分前